Lower steroid dose study for children with lupus nephritis
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old and weigh at least 44 pounds (20 kg).
- You have been diagnosed with lupus (SLE) and have a kidney biopsy showing active inflammation (class III, IV, III+V, or IV+V).
- At screening, your 24-hour urine protein is at least 1 gram (or 25 mg per kg), or your urine protein-to-creatinine ratio is at least 1.0.
- Your white blood cell count is at least 3.0 and lymphocyte count at least 1.0 (standard blood test results).
- You have not received high-dose steroids by IV in the past, and any steroid use in the last 2 weeks has been limited to 30 mg prednisone per day (or 1 mg per kg per day) or less.
- You are willing to follow the study plan and have signed an informed consent form (parent or guardian consent if needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and protect kidney function.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This study is looking for biomarkers (clues in your blood, urine, or tissue) that can help predict how well lupus nephritis (kidney inflammation caused by lupus) responds to treatment. It focuses on people who have active kidney disease and are either starting treatment or have been on a stable treatment for at least a month.
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
Hear when a new Childhood-onset Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.